Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma

Oncoimmunology 2025 December [Link] Sophie Rovers, Jonas Van Audenaerde, Ruben Verloy, Jorrit De Waele, Louize Brants, Christophe Hermans, Ho Wa Lau, Céline Merlin, Maria Möller Ribas, Peter Ponsaerts, Steven Van Laere, Filip Lardon, An Wouters, Scott A Fisher, Jan van Meerbeeck, Elly Marcq, Evelien Smits Abstract Pleural mesothelioma (PM) is an aggressive cancer caused by…

Read More

Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses

Pathology, Research, and Practice 2025 July [Link] Zhenghua Zhang, Wenjun Gao, Feng Yuan, Yubin Hu, Xiaoyu Tuo, Liangping Luo, Xiaonan Tang, Shasha Shen, Yang Tian, Dan Han Abstract Objective: Chemotherapy may modulate PD-L1 expression in malignant pleural mesothelioma (MPM), influencing immune checkpoint inhibitor (ICI) efficacy. We compared cisplatin (CDDP) and pemetrexed (PEM) on PD-L1 dynamics…

Read More

A four-miRNA signature as a potential biomarker of malignant mesothelioma patients from hand-spinning asbestos exposed area in Eastern China

Ecotoxicology and Environmental Safety 2025 July 1 [Link] Lijin Zhu, Shibo Ying, Xin Su, Wenke Yu, Kaili Yan, Wei Shen, Shuaiyue Hu, Zhaoqiang Jiang, Hailing Xia, Lingfang Feng, Yan Zeng, Junqiang Chen, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive malignant tumor of mesothelial origin that develops mainly in the parietal pleura…

Read More

KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma

Cancer Science 2025 May 23 [Link] Takashi Kijima, Terufumi Kato, Yasushi Goto, Kozo Kuribayashi, Koji Mikami, Yoshiki Negi, Shuji Murakami, Tatsuya Yoshida, Masae Homma, Akira Wakana, Kazuo Noguchi, Nobukazu Fujimoto Abstract Pleural mesothelioma (PM) is an inflammatory cancer linked with asbestos exposure and has a poor prognosis. We report results of the phase 1b KEYNOTE-A17…

Read More

Epithelial-Mesenchymal Plasticity in the D-Meso-Sonobe Mesothelioma Cell Line: A Putative Model of Epithelial-Mesenchymal Transition in Mesothelioma

Thoracic Cancer 2025 May [Link] Hiroshi Okubo, Yuki Hanamatsu, Chiemi Saigo, Sonobe Hiroshi, Tamotsu Takeuchi Abstract Epithelial-mesenchymal transition (EMT) plays a crucial role in carcinogenesis, including mesothelioma. D-Meso-Sonobe is a deciduoid-type mesothelioma cell line with morphological features similar to those of epithelioid cells. Here, we report that D-Meso-Sonobe cells exhibit spindle cell mesenchymal features under…

Read More

From asbestos exposure to carcinogenesis: Transcriptomic signatures in malignant pleural mesothelioma

Experimental and Molecular Pathology 2025 May 20 [Link] Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angela Rina, Francesca Mari, Maria Palmieri, Antonio Giordano, Elisa Frullanti Abstract Background: The incidence of malignant pleural mesothelioma (MPM) has surged due to widespread asbestos exposure, particularly since the mid-20th century. Despite significant advancements in cancer treatment,…

Read More

A bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023

Journal of Thoracic Cancer 2025 April 30 [Link] Sheng Chen, Ce Zhao, Ruiqi Liu, Wenjie Jiao Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor originating from the mesothelial lining of the pleural cavity. It is characterized by extensive nodular pleural thickening and has a propensity to invade the pleural adipose tissue and adjacent…

Read More

Diagnostic value of cyclin D1 immunohistochemistry in differentiating malignant mesothelioma from reactive mesothelial proliferation

Annals of Diagnostic Pathology 2025 October [Link] Döndü Nergiz, Arsenal Sezgin Alikanoğlu, Dinç Süren Abstract Introduction: Although morphologic assessment carries utmost importance in differentiating malignant mesotheliomas (MM) from reactive mesothelial proliferations (RMP), sometimes it may fail to clearly differentiate between these two entities. The aim of this study is to evaluate the potential role of…

Read More

Breaking Through: Immunotherapy Innovations in Pleural Mesothelioma

Clinical Lung Cancer 2025 April 22 [Link] Amalia A Sofianidi, Nikolaos K Syrigos, Kevin G Blyth, Andriani Charpidou, Ioannis A Vathiotis Abstract The prognosis of pleural mesothelioma (PM) is poor and conventional chemotherapy regimens have shown limited antitumor activity. Recent use of immune checkpoint inhibitors (ICIs) has shown promise, with CheckMate-743 trial establishing nivolumab plus…

Read More

Deoxypodophyllotoxin inhibited the growth of malignant pleural mesothelioma by inducing necroptosis and mitotic catastrophe

Phytomedicine 2025 July 25 [Link] Cheng Zhong, Shenqi Wang, Jingyuan Zhang, Qi Zheng, Yuqiong Lei, Yongle Xu, Tao Ren, Rong Sun Abstract Background: Malignant pleural mesothelioma (MPM) is an extremely aggressive cancer with a poor prognosis and limited effective treatment options. However, recent studies have shown that targeting microtubule regulation is a viable approach for…

Read More